Stockscreener 앱 받기
3.28
2.96%
-0.10
시간 외 거래:
3.28
전일 마감가:
$3.38
열려 있는:
$3.34
하루 거래량:
251.21K
Relative Volume:
0.65
시가총액:
$162.82M
수익:
$230.47M
순이익/손실:
$30.28M
주가수익비율:
5.377
EPS:
0.61
순현금흐름:
$38.86M
1주 성능:
+1.39%
1개월 성능:
+7.89%
6개월 성능:
-3.24%
1년 성능:
-13.91%
1일 변동 폭
$3.255
$3.355
1주일 범위
$3.255
$3.45
52주 변동 폭
$2.225
$4.13
Puma Biotechnology Inc Stock (PBYI) Company Profile
명칭
Puma Biotechnology Inc
전화
(424) 248-6500
주소
10880 WILSHIRE BLVD., LOS ANGELES, CA
PBYI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
3.28 | 160.58M | 230.47M | 30.28M | 38.86M | 0.61 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Underperform |
| 2019-10-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-10 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-01-17 | 개시 | Leerink Partners | Mkt Perform |
| 2019-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-11-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-11-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 개시 | Goldman | Sell |
| 2018-05-11 | 재확인 | Stifel | Buy |
| 2017-11-10 | 재확인 | Citigroup | Buy |
| 2017-11-10 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 재확인 | Stifel | Buy |
| 2017-09-11 | 재확인 | Credit Suisse | Outperform |
| 2017-07-10 | 재개 | Leerink Partners | Outperform |
| 2017-06-06 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 재확인 | RBC Capital Mkts | Sector Perform |
모두보기
Puma Biotechnology Inc 주식(PBYI)의 최신 뉴스
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Puma Biotechnology Inc (PBYI) Forecast: Revisiting The Past To Gain Insights For The Future - Stocksregister
Puma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable Quality - Yahoo Finance
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by Wells Fargo & Company MN - Defense World
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock - Nasdaq
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - MSN
Puma Biotechnology First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Earnings Call Transcript - Insider Monkey
Puma Biotech CCO Jeff Ludwig departs, no replacement named By Investing.com - Investing.com Canada
Puma Biotech CCO Jeff Ludwig departs, no replacement named - Investing.com
Puma Biotechnology, Inc. Announces Termination of Jeff J. Ludwig as Chief Commercial Officer - marketscreener.com
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - Yahoo Finance
Puma Biotechnology Terminates Chief Commercial Officer - TipRanks
Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Positive Q1 2025 Earnings - TipRanks
Puma Biotech Q1 2025 slides: NERLYNX revenue up 7% YoY despite quarterly decline - Investing.com Canada
Puma Biotech: Q1 Earnings Snapshot - The Washington Post
Cautious Hold Rating on Puma Biotechnology Amid Declining Sales and Uncertain Trial Outcomes - TipRanks
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts By Investing.com - Investing.com UK
Puma Biotechnology Reports First Quarter Financial Results - BioSpace
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts - Investing.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2025 - BioSpace
Check out these key findings about Puma Biotechnology Inc (PBYI) - Sete News
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients - The Manila Times
Er-Kim Announces Exclusive Distribution Agreement with Puma - GlobeNewswire
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results - BioSpace
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why - MSN
Is The Options Market Predicting A Spike In Puma Biotechnology Stock? - Barchart.com
Is the Options Market Predicting a Spike in Puma Biotechnology Stock? - Yahoo Finance
Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential - Seeking Alpha
Puma Biotechnology Inc (PBYI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):